Tsubota Laboratory Incorporated Logo

Tsubota Laboratory Incorporated

R&D company developing treatments for ophthalmology and CNS disorders.

4890 | T

Overview

Corporate Details

ISIN(s):
JP3535700003
LEI:
Country:
Japan
Address:
新宿区信濃町35 慶應義塾大学信濃町キャンパス2号館9階CRIK信濃町E7

Description

Tsubota Laboratory Incorporated is a research and development company that originated as a startup from Keio University. It is engaged in the creation of pharmaceuticals and medical devices. The company's primary focus is on ophthalmology, developing solutions for conditions such as myopia, dry eye, and presbyopia. Additionally, it explores treatments for central nervous system (CNS) disorders and brain diseases. The corporate strategy centers on out-licensing its developed pipelines to commercial partners. A notable pipeline is a therapeutic candidate designed to curtail the progression of myopia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:34
確認書
Japanese 9.0 KB
2025-11-12 07:33
半期報告書-第14期(2025/04/01-2026/03/31)
Japanese 195.3 KB
2025-06-27 04:35
臨時報告書
Japanese 23.3 KB
2025-06-26 09:02
確認書
Japanese 9.4 KB
2025-06-26 09:01
内部統制報告書-第13期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-26 09:01
有価証券報告書-第13期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 08:02
確認書
Japanese 9.0 KB
2024-11-14 08:02
半期報告書-第13期(2024/04/01-2025/03/31)
Japanese 201.7 KB
2024-06-27 04:10
内部統制報告書-第12期(2023/04/01-2024/03/31)
Japanese 22.8 KB
2024-06-27 04:09
確認書
Japanese 8.9 KB
2024-06-27 04:08
有価証券報告書-第12期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-02-14 07:11
確認書
Japanese 9.0 KB
2024-02-14 07:10
四半期報告書-第12期第3四半期(2023/10/01-2023/12/31)
Japanese 160.1 KB
2023-11-13 07:06
確認書
Japanese 9.0 KB
2023-11-13 07:02
四半期報告書-第12期第2四半期(2023/07/01-2023/09/30)
Japanese 193.0 KB

Automate Your Workflow. Get a real-time feed of all Tsubota Laboratory Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tsubota Laboratory Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tsubota Laboratory Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.